Stella Pharma's operating loss widened to ¥498mn in the first half of the year to March 2027, from ¥298mn a year earlier, as the cost of moving production of its boron neutron capture therapy (BNCT) drug to a new manufacturer weighed on overhead.
The cost of moving production
Sales fell 12.5% to ¥175mn. Gross margin held at the prior year's level, but selling and administrative expenses rose 38.5% to ¥643.6mn, a net increase of ¥178.9mn. Production-transfer costs rose ¥191.8mn, and the company's results briefing deck says they make up about 90% of the factors behind the increase; declines in other items leave the net rise smaller.
A ¥53mn subsidy booked as non-operating income narrowed the ordinary loss to ¥467mn. The net loss was ¥469mn. Research spending fell 18.0% to ¥107.7mn, partly because about ¥32mn of trial costs slipped into the second half.
Supply is still the bottleneck
The deck says the former contract manufacturer's bankruptcy halted the production line and made rebuilding stable supply the company's top priority. Stella Pharma filed a partial change application with the Pharmaceuticals and Medical Devices Agency in August 2026 to add a manufacturing site. The application is now under review and GMP compliance inspection, with approval expected around January 2027.
Only after that approval does the deck show production, domestic supply and shipments to Hainan resuming. The full-year plan assumes sales of ¥1,038mn, against ¥323mn in the prior year, with an operating loss of ¥696mn. A footnote schedules Hainan shipments for the fourth quarter.
The approval in context
The deck also records the November 16 approval of the drug for recurrent meningioma. Earlier Tokyo Brief coverage covers that decision. The new disclosure adds the manufacturing step still ahead: the site approval, not the indication, decides when supply restarts.
